Brandi Quintanilla, DO, MS – PGY3

Awards & Honors:

• NIMH Outstanding Resident Program, Honorable Mention, 2024
• Scholar Trainee Guest Speaker, International Conference on Health Disparities: Psychiatric and Medical Comorbidities Related to Opioid and Alcohol Use Disorders, UTRGV SOM, 2023.
• Society of Biological Psychiatry Travel Award, 2023
• American College of Neuropsychopharmacology Travel Award (ACNP), 2022
• Scholar Trainee Guest Speaker, International Conference on Health Disparities: Treatment and Recovery from Opioid and Alcohol Use Disorders and Related Comorbidities, UTRGV SOM, 2022
• Research Colloquium for Junior Investigators, American Psychiatric Association (APA), 2022

Publications:

• Quintanilla, B., Zarate, C. A., Jr, & Pillai, A. (2024). Ketamine’s mechanism of action with an emphasis on neuroimmune regulation: can the complement system complement ketamine’s antidepressant effects?. Molecular psychiatry, 10.1038/s41380-024-02507-7. Advance online publication. https://doi.org/10.1038/s41380-024-02507-7
• Quintanilla B, Medeiros GC, Greenstein D, Yuan P, Johnston JN, Park LT, Goes F, Gould TD, Zarate Jr. CA. “Kappa opioid receptor plasma levels are associated with sex and diagnosis of major depressive disorder but not response to ketamine” JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2022.

Abstracts/ Presentations:

• Quintanilla B, Medeiros GC, Greenstein D, Yuan P, Johnston JN, Park LT, Goes F, Gould TD, Zarate Jr. CA. Kappa opioid receptor plasma levels are associated with sex and diagnosis of major depressive disorder but not response to ketamine. American Psychiatric Association (APA) Research Colloquium for Junior Investigators, New Orleans, LA, 2022.
• Quintanilla B. Management of dementia related aggression, Psychiatry Faculty, Houston, TX. November, 2021
• Quintanilla B, Greenstein D, Bartosh A, Tripathi A, Yuan P, Zarate Jr. CA., Pillai A. Can the complement system complement Ketamine’s anti-depressive effects? Poster presented at ACNP 2022.